Clinical Report: Evaluation of Serum and Urinary Golgi Membrane Protein 1 as Biomarkers
Overview
This study investigates serum and urinary Golgi membrane protein 1 (GOLM1/GP73) as biomarkers for staging chronic kidney disease (CKD). Findings indicate that serum G73 levels correlate with CKD severity, while urinary G73 levels decline with advancing disease.
Background
Chronic kidney disease (CKD) affects a significant portion of the global population and is associated with high morbidity and mortality. Current biomarkers for CKD, such as serum creatinine and albuminuria, have limitations in reflecting tubular health and disease progression. There is a need for novel biomarkers that can provide insights into both systemic disease burden and local tubular function.
Data Highlights
CKD Stage
Serum G73 (ng/mL)
Urinary G73 (ng/mL)
Healthy
47.2
Not reported
CKD 1-3
62.2
Not reported
CKD 4-5
96.1
Not reported
CKD 5D
89.9
Not reported
Key Findings
Serum G73 levels increase with CKD severity, peaking at CKD stage 4-5.
Urinary G73 and the urine G73-to-creatinine ratio decline as CKD progresses.
Adding serum G73 to clinical models improves discrimination for advanced CKD.
Serum G73 shows modest ability to distinguish AKI from CKD.
Kidney tissue expression of GP73 remains weak and unchanged across CKD stages.
Clinical Implications
Serum and urinary G73 may serve as non-invasive biomarkers for CKD staging.
Conclusion
Serum G73 is associated with CKD severity, while urinary G73 reflects tubular health.
The judgment stemmed from controlled-substance prescriptions issued after William C. Gardner, DDS, no longer held the state licensure required for federal prescribing authority.
